Albert Labs going public soon.
VANCOUVER, BC, June 3, 2021 /CNW/ – ME Resource Corp (“MEC” or the “Company”) (CNSX: MEC) (OTC: MEEXF) announced today that the Company has submitted an initial listing statement (the “Listing Statement”) supporting its application for listing on the Canadian Securities Exchange (“CSE”) in conjunction with its previously announced reverse take-over transaction (“RTO”) with Albert Labs (“Albert Labs”). Albert Labs, a psychedelics drug developer using accelerated pathways to address urgent and unmet mental health needs across Europe. The Listing Statement submission will initiate a consulting phase by the CSE with the Company in preparation for subsequent listing (the “Listing”) of the common shares in the capital of the resulting issuer Albert Labs, subject to satisfying requirements of the CSE. While there can be no guarantee the Common Shares will be successfully listed on the CSE, Albert Labs and the Company work towards the listing execution of definitive documents and closing with respect to the RTO definitive agreement dated March 5th.
Chand Jagpal, the Chief Operations Officer of Albert Labs, stated “The much anticipated submission of the listing statement represents a significant milestone for Albert Labs. We’re excited to move towards our goal of becoming a public company to attract growth capital and enable Albert Labs to continue towards its goal of being a worldwide leader and provide accelerated access to psychedelics medicines and therapy”
Albert Labs leverages Real-World Evidence (RWE) studies in the UK and across Europe to accelerate access to its proprietary natural psychedelics-based therapies for patients with urgent, unmet mental health needs. For more information about the company, please see below:
Business of Albert Labs Inc.
Listen to Albert Labs’ Chief Medical Officer, Dr. Malcolm Barratt-Johnson introduce Albert Labs and their mission here (https://youtu.be/_yMkrZgeU7k).
Albert Labs is the first psychedelic company to leverage Real World Evidence (RWE) Studies to accelerate access to approved psychedelic medicines in hospital settings across the UK and Europe to treat mental health indications with urgent and high unmet needs. Albert will own the wide dataset collected in the studies to develop an IP stack around unique formulation and delivery mechanisms of its approved psychedelics drug therapy.
A laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies. Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring proprietary natural psilocybin-assisted therapy to the UK and Europe before expanding globally. Albert Labs is going through an RTO with a listing expected soon. More details can be found in our previous news release.
Albert Labs has submitted applications for psychedelic research and a dealer’s license which will allow the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline in its lab in Burnaby, BC Canada. These Health Canada licenses will also allow the company to export, test, and conduct R&D on these controlled substances.
Watch a short “About Albert Labs” video and hear more of the investment opportunity here (https://youtu.be/otQezIvmIXI).
ON BEHALF OF THE BOARD OF DIRECTORS
ME Resource Corp.
Dr Michael Raymont, Chairman
Accelerating patient access to safe and effective psychedelic-assisted therapy.
Cautionary Statement
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate.
The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements.
Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise unless required by the applicable securities laws.
SOURCE Albert Labs Inc.
